- Home
- ACEL vs DSGN Comparison
ACEL vs DSGN Comparison
Compare ACEL & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACEL | DSGN |
|---|---|---|
| Founded | 2009 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 996.0M | 819.6M |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ACEL | DSGN |
|---|---|---|
| Price | $11.66 | $11.18 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $14.67 | ★ $15.25 |
| AVG Volume (30 Days) | 296.4K | ★ 1.1M |
| Earning Date | 05-05-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 46.34 | N/A |
| EPS | ★ 0.17 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.07 | N/A |
| Revenue Next Year | $2.81 | N/A |
| P/E Ratio | $68.47 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.55 | $3.33 |
| 52 Week High | $13.31 | $17.25 |
Technical Indicators
Market Signals| Indicator | ACEL | DSGN |
|---|---|---|
| Relative Strength Index (RSI) | 47.34 | 40.09 |
| Support Level | $10.86 | $9.25 |
| Resistance Level | $12.57 | $13.54 |
| Average True Range (ATR) | 0.36 | 1.32 |
| MACD | -0.03 | -0.52 |
| Stochastic Oscillator | 34.69 | 16.83 |
Price Performance
Historical ComparisonAbout ACEL Accel Entertainment Inc.
Accel Entertainment Inc is a distributed gaming and local entertainment operator in the United States. It is engaged in the installation, maintenance, operation, and servicing of gaming terminals and related equipment, redemption devices that disburse winnings and contain automated teller machine (ATM) functionality, and amusement devices in authorized non-casino locations such as restaurants, bars, convenience stores, liquor stores, truck stops, and grocery stores. The Company also operates stand-alone ATMs in gaming and non-gaming locations. It generates revenue from Net gaming, Amusement, Manufacturing, ATM fees, and others.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.